Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen receptor T-cell therapy, according to results of a retrospective cohort ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Series A funding round led by Angelini Ventures’, the investment arm of Italian industrial group Angelini Industries.

The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

In the biotechnology and chemical spaces, genus claims are often sought by patent applicants to protect not only a specific product of interest, ...

Kash is known to Israelis mainly for his books "Success Tactics You Won't Learn in Business School" "Freedom from Disease" ...

As principal and co-founder of Sierra Pacific Constructors and a second-generation builder, Cary Gerhardt remains active in ...

Sierra Pacific Constructors principal and cofounder Ken La Spada is responsible for a wide diversity of activities for SPC, ...

Detailed price information for Senti Biosciences Inc (SNTI-Q) from The Globe and Mail including charting and trades.